Trials / Terminated
TerminatedNCT01433536
Evaluation of Circulating Osteogenic Factors in Trauma Patients
Evaluation of Circulating Osteogenic Factors in Trauma Patients (BMP-9)
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (actual)
- Sponsor
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Bone fractures in traumatic brain-injured and spinal cord-injured patients often heal faster than in other patients. However, such patients are also occasionally prone to bone formation in soft tissues such as muscle. This process is called heterotopic ossification and tends to occur around joints. Patients with heterotopic ossification often suffer from complications such nerve compression, ankylosis, chronic pain, osteoporosis, and infections. Loss of movement can also interfere with function and the quality of life of patients already experiencing difficulties associated with their trauma. Positioning, transfers, and hygiene become difficult and even impossible, which worsens the loss of autonomy. Previous research has suggested that an osteoinductive factor (which has the capacity to induce the formation of bone) may be released into the bloodstream following a head or spinal cord injury. The investigators laboratory has shown that a growth factor called BMP-9, when injected into a damaged mouse muscle, has the ability to cause strong ossification in damaged muscle. The investigators would like to find out whether the levels of BMP-9 and/or its receptor (which is called ALK1) increase after traumatic brain and spinal cord injuries that occur at the same time as serious orthopaedic traumas. The main goal of the investigators study is thus to determine whether BMP-9 levels increase in the serum of trauma patients.
Conditions
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2011-09-14
- Last updated
- 2018-01-24
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01433536. Inclusion in this directory is not an endorsement.